Genelux (NASDAQ:GNLX) Shares Down 3.8%
Genelux (NASDAQ:GNLX) Shares Down 3.8%
Genelux Co. (NASDAQ:GNLX – Get Rating) dropped 3.8% during mid-day trading on Thursday . The stock traded as low as $27.24 and last traded at $28.50. Approximately 36,234 shares traded hands during trading, a decline of 76% from the average daily volume of 151,273 shares. The stock had previously closed at $29.63.
Analysts Set New Price Targets
Separately, Benchmark initiated coverage on Genelux in a report on Wednesday, February 15th. They set a "speculative buy" rating and a $10.00 target price for the company.
Genelux Stock Down 5.5 %
Genelux Company Profile
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Articles
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
Genelux Co. (NASDAQ:GNLX – Get Rating) dropped 3.8% during mid-day trading on Thursday . The stock traded as low as $27.24 and last traded at $28.50. Approximately 36,234 shares traded hands during trading, a decline of 76% from the average daily volume of 151,273 shares. The stock had previously closed at $29.63.
吉勒聯盟股份有限公司（納斯達克：GNLX-獲得評級）在星期四中午交易期間下降了 3.8%。該股票的交易價格低至 27.24 美元，最後交易價格為 28.50 美元。交易期間約有 36,234 股股份成交手，較每日平均成交量 151,273 股下跌 76%。該股票之前已收盤 29.63 美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Benchmark initiated coverage on Genelux in a report on Wednesday, February 15th. They set a "speculative buy" rating and a $10.00 target price for the company.
另外，基準在 2 月 15 日星期三的一份報告中啟動了對基納盧經濟聯盟的報導。他們為該公司設定了「投機性買入」評級和 10.00 美元的目標價格。
Genelux Stock Down 5.5 %
基因盧股票下降 5.5%
Genelux Company Profile
日內盧公司簡介
(Get Rating)
(取得評分)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
格內盧公司是一家臨床階段的生物製藥公司。它專注於為患有侵略性和/或難以治療的實體腫瘤類型的患者開發下一代單體免疫療法的管道。該公司最先進的候選產品 Olvi-VEC 是一種專有的，改性的疫苗病毒菌株，一種穩定的 DNA 病毒。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
- 獲取有關基因盧經濟聯盟（GNLX）的研究報告的免費副本
- KB 首頁強勁業績提升價格
- 耐嚼的股票正在建立長期盈利增長
- 為什麼華爾街喜歡這 3 竹篙股票
- 低容量邦吉暴跌提出了機會
- 卡瓦納今年可能能夠達到盈利能力
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
接收基納盧日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Genelux 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧